Cybrexa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of CBX-12 (alphalex™-exatecan) in Advanced or Metastatic Refractory Solid Tumors

NEXT STORY
Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting
PREV STORY
G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Axiom Medical, an innovator in occupational health services for employers, announced it has exceeded ten million check ins on the leading edge CheckIn2Work mobile app

author_avatar
NASDAQ Market News

VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16

author_avatar
NASDAQ Market News

CorMedix Receives Complete Response Letter From FDA for DefenCath™ Catheter Lock Solution

author_avatar
NASDAQ Market News